{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:16:41Z","timestamp":1792088201407,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.dsx.2022.102640","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T14:24:34Z","timestamp":1665757474000},"page":"102640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials"],"prefix":"10.1016","volume":"16","author":[{"given":"Hikmat","family":"Permana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo Audi","family":"Yanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-9776","authenticated-orcid":false,"given":"Timotius Ivan","family":"Hariyanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"S 01","key":"10.1016\/j.dsx.2022.102640_bib1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1055\/a-1018-9078","article-title":"Definition, classification and diagnosis of diabetes mellitus","volume":"127","author":"Petersmann","year":"2019","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"2","key":"10.1016\/j.dsx.2022.102640_bib2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00125-019-05039-w","article-title":"2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"63","author":"Buse","year":"2020","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.dsx.2022.102640_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13435","article-title":"Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials","volume":"23","author":"Iqbal","year":"2022","journal-title":"Obes Rev"},{"key":"10.1016\/j.dsx.2022.102640_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/2042018821997320","article-title":"GLP-1 receptor agonists: an updated review of head-to-head clinical studies","volume":"12","author":"Trujillo","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.dsx.2022.102640_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109031","article-title":"Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): a systematic review, meta-analysis, and meta-regression","volume":"179","author":"Hariyanto","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.dsx.2022.102640_bib6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J\u00a0Clin Invest"},{"issue":"12","key":"10.1016\/j.dsx.2022.102640_bib7","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.2337\/db11-0979","article-title":"Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans","volume":"60","author":"Christensen","year":"2011","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.dsx.2022.102640_bib8","doi-asserted-by":"crossref","first-page":"E418","DOI":"10.1210\/jc.2013-3644","article-title":"Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes","volume":"99","author":"Christensen","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.dsx.2022.102640_bib9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cmet.2019.07.013","article-title":"Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake","volume":"30","author":"Adriaenssens","year":"2019","journal-title":"Cell Metabol"},{"key":"10.1016\/j.dsx.2022.102640_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101090","article-title":"Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease","volume":"46","author":"Baggio","year":"2021","journal-title":"Mol Metabol"},{"issue":"1","key":"10.1016\/j.dsx.2022.102640_bib11","article-title":"Tirzepatide, a dual GIP and GLP-1 receptor agonist, mediates its anorectic effect in preclinical models of obesity due to a reduction in homeostatic and hedonic related feeding","volume":"63","author":"Cosgrove","year":"2020","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.dsx.2022.102640_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13300-020-00981-0","article-title":"The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials","volume":"12","author":"Min","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.dsx.2022.102640_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metabol"},{"key":"10.1016\/j.dsx.2022.102640_bib14","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2147\/DMSO.S351982","article-title":"The emerging role of dual GLP-1 and GIP receptor agonists in glycemic management and cardiovascular risk reduction","volume":"15","author":"Rizvi","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.dsx.2022.102640_bib15","first-page":"372","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.dsx.2022.102640_bib16","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"7414","key":"10.1016\/j.dsx.2022.102640_bib17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.dsx.2022.102640_bib18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"10.1016\/j.dsx.2022.102640_bib19","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/biom.12817","article-title":"Quantifying publication bias in meta-analysis","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics"},{"issue":"10160","key":"10.1016\/j.dsx.2022.102640_bib20","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.dsx.2022.102640_bib21","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/dom.13979","volume":"22","author":"Frias","year":"2020","journal-title":"Diabetes Obes Metabol"},{"issue":"2","key":"10.1016\/j.dsx.2022.102640_bib22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/dom.14572","article-title":"A\u00a0phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes","volume":"24","author":"Furihata","year":"2022","journal-title":"Diabetes Obes Metabol"},{"issue":"10295","key":"10.1016\/j.dsx.2022.102640_bib23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.dsx.2022.102640_bib24","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"SURPASS-2 investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10300","key":"10.1016\/j.dsx.2022.102640_bib25","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"issue":"10313","key":"10.1016\/j.dsx.2022.102640_bib26","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.dsx.2022.102640_bib27","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.dsx.2022.102640_bib28","unstructured":"Eli Lily and Company. A study of tirzepatide (LY3298176) compared to dulaglutide in participants with type 2 diabetes (SURPASS J-mono). ClinicalTrials.gov. NCT03861052."},{"key":"10.1016\/j.dsx.2022.102640_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170230","article-title":"Recent advances of GIP and future horizons","volume":"125","author":"Holst","year":"2020","journal-title":"Peptides"},{"issue":"11\u201312","key":"10.1016\/j.dsx.2022.102640_bib30","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1055\/s-2004-826162","article-title":"Physiology of GIP--a lesson from GIP receptor knockout mice","volume":"36","author":"Yamada","year":"2004","journal-title":"Horm Metab Res"},{"issue":"7","key":"10.1016\/j.dsx.2022.102640_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040156","article-title":"GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.dsx.2022.102640_bib32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.metabol.2019.04.014","article-title":"The incretin system in healthy humans: the role of GIP and GLP-1","volume":"96","author":"Holst","year":"2019","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.dsx.2022.102640_bib33","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3390\/ph14100991","article-title":"Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized phase II\/III trials","volume":"14","author":"Bhagavathula","year":"2021","journal-title":"Pharmaceuticals"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402122002545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402122002545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:20:36Z","timestamp":1761729636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402122002545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1871402122002545"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102640","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: A systematic review and meta-analysis of randomized clinical trials","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102640","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Diabetes India. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102640"}}